HCC1428 Xenograft Model Service for Breast Cancer

The HCC1428 xenograft model is an essential in vivo tool for investigating the mechanisms of Estrogen Receptor-positive (ER+) breast cancer and evaluating the efficacy of novel endocrine therapies and targeted agents. Alfa Cytology provides a comprehensive and highly standardized HCC1428 xenograft model service, utilizing optimized inoculation protocols and expert scientific oversight to ensure the highest degree of translational relevance for your preclinical programs.

Overview of HCC1428 Xenograft Model for Breast Cancer

The HCC1428 cell line is a human mammary carcinoma model originally derived from a pleural effusion of a patient with metastatic breast cancer. It is recognized as a key model for Luminal breast cancer research, specifically characterized by its strong expression of the Estrogen Receptor (ER). Unlike many aggressive triple-negative models, HCC1428 maintains a more differentiated epithelial phenotype and exhibits dependency on estrogen signaling, making it a critical platform for studying hormone-responsive disease pathways and secondary resistance to treatments such as aromatase inhibitors or SERDs (Selective Estrogen Receptor Degraders).

When established in vivo as a xenograft in immunocompromised mice, HCC1428 cells form stable tumors that closely mimic the histological and hormonal characteristics of clinical Luminal breast cancer. This model typically requires supplemental estrogen support for optimal engraftment and consistent growth kinetics, a technical nuance that Alfa Cytology has mastered through extensive internal validation. By recapitulating the molecular profile of ER+ breast cancer, the HCC1428 model allows researchers to conduct high-fidelity efficacy screening, pharmacodynamic (PD) profiling, and combination therapy assessments within a robust biological framework.

Fig 1. Higher tumorsphere-forming ability is shown in HCC1428-long-term estrogen deprivation (LTED) cells than in HCC1428 cells. Images of tumorspheres were captured (left) and quantified (right). (Fukuoka M, et al., 2022)

Cell Line Information: HCC1428

The HCC1428 cell line is defined by its epithelial morphology and clear hormone receptor profile, ensuring consistent results across both in vitro screening and in vivo validation.

Alfa Cytology is dedicated to providing high-quality preclinical data through meticulous study execution and rigorous quality control. Our oncology experts specialize in the management of hormone-dependent models, ensuring that every HCC1428 study is supported by precise hormonal supplementation and authenticated cellular material.

Our Services

Workflow of HCC1428 Xenograft Model Construction

Alfa Cytology follows a standardized and scientifically rigorous workflow to establish the HCC1428 xenograft model:

• Cell Culture & QC: HCC1428 cells are expanded in specialized growth media. We perform rigorous quality control, including STR authentication and mycoplasma screening, to ensure cell identity and high viability prior to inoculation.
• Host Preparation & Hormone Supplementation: Standardized immunocompromised mice are selected. Given the ER+ nature of the model, mice are typically supplemented with exogenous estrogen (e.g., via subcutaneous pellets) to support consistent tumor engraftment.
• Inoculation Procedure: A precisely calibrated suspension of HCC1428 cells is prepared, often utilizing a biological matrix carrier to enhance initial in vivo growth. Injections are performed via subcutaneous or orthotopic routes.
• Growth Monitoring: Following inoculation, tumor volumes and animal body weights are monitored longitudinally using precision digital calipers. This allows us to establish accurate growth curves while ensuring strict adherence to animal welfare standards.
• Randomization & Grouping: Once tumors reach a consistent and statistically relevant volume, animals are randomized into treatment and control cohorts to ensure balanced baseline parameters before therapeutic dosing.

Fig 2. HCC1428 Xenograft Model Construction Workflow

Case Study - HCC1428 Xenograft Model Development

In a recent study conducted at Alfa Cytology, the HCC1428 xenograft model was successfully utilized to evaluate a novel SERD candidate in combination with a CDK4/6 inhibitor. Our technical team achieved highly reproducible tumor engraftment and uniform growth kinetics across all study arms, providing a clear window for observing therapeutic synergy. The in vivo data revealed significant tumor growth inhibition and a superior response in the combination group compared to monotherapy.

Why Choose Alfa Cytology?

• Hormone-Dependent Model Expertise: Specialized knowledge in managing ER+ models requiring complex supplementation.
• Technical Precision: Standardized inoculation and longitudinal monitoring protocols that minimize experimental variability.
• Comprehensive Downstream Analysis: Full capacity for IHC receptor staining, PK/PD tissue analysis, and biomarker evaluation.
• Scientific Rigor: Commitment to high-fidelity data and transparent communication throughout the study lifecycle.

Contact Us

Are you looking to validate your next therapeutic candidate for ER+ breast cancer using the robust HCC1428 xenograft platform? The expert scientific team at Alfa Cytology is ready to provide tailored experimental designs and technical execution to meet your research milestones. Please reach out to us today to discuss your project requirements, or contact us directly to request a project consultation and a detailed quotation.

For research use only. Not intended for any clinical use.